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In our study, we evaluated the relationship
between the glucose levels on admission and
the angiographic ﬁndings during primary stent
implantation in patients with ST-elevation acute
myocardial infarction (STEMI). We did not inves-
tigate the effect of insulin therapy, therefore we
could not conclude whether tight control of glu-
cose levels is sufﬁcient to improve the prognosis
in patients with STEMI. Indeed, some clinical tri-
als failed to evaluate the efﬁcacy of GIK therapy. dLetters to the Editor
owever, there are some important problems in
hese trials. First, most of subjects in these tri-
ls were treated by thrombolytic therapy. In the
REATE-ECLA trial, primary coronary intervention
as performed in only 9% of all subjects [1]. More-
ver, the glucose levels 24 h after randomization in
he GIK treatment group were higher than in the
ontrol group in the combined OASIS-6 and CREATE-
CLA trial analysis (155mg/dl vs 135mg/dl) [2].
yperglycemia and hyperinsulinemia lead to pro-
oagulant and pro-inﬂammatory states. In the GIPS
I study, blood glucose levels after randomization
ere not recorded [3]. We think that the aim of
nsulin therapy in STEMI is to normalize the glucose
evel, not to infuse the insulin—glucose—potassium.
ecently, Kosiborod et al. [4] have reported that
lucose normalization after admission is associated
ith better survival in hyperglycemic patients with
MI whether or not they receive insulin therapy. And
hey have suggested that the in-hospital mortality
ate increased according to the elevation of glucose
evel above the threshold of 130mg/dl.
We also hope that large, randomized clinical
rials are warranted to deﬁne the optimal target
lucose level in patients with STEMI.
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